Hansoh Pharma's self-developed B7-H3 targeted antibody-drug conjugate HS-20093 combined with Atezolizumab obtained NMPA breakthrough therapy designation.

19:32 16/04/2026

Hansen Pharmaceuticals (03692) announced that on April 16, 2026, the group's self-developed B7-H3 targeted antibody-drug conjugate (ADC) injection HS-20093, in combination with atezolizumab, was approved by the National Medical Products Administration (NMPA) of China as a breakthrough therapy drug. The proposed indication is for locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed or recurred after previous platinum-based chemotherapy and is negative for driver genes.

Hansoh Pharma (03692) announced that on April 16, 2026, the group's self-developed B7-H3 targeting antibody-drug conjugate (ADC) injection HS-20093, in combination with atezolizumab, has been granted breakthrough therapy designation by the China National Medical Products Administration (NMPA). It is intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with no driver gene mutations that has progressed or recurred after platinum-based chemotherapy.

PALASINO (02536) appoints Wong Ai Hui as Chief Financial Officer, Company Secretary, Authorized Representative and Legal Process Agent.

XD INC (02400) spent HK$7.8128 million on April 16th to repurchase 120,000 shares.

ZYY (08223) has successfully issued a total of 86 million subscribed shares, raising approximately 42.5 million Hong Kong dollars.

PALASINO (02536) appoints Wong Ai Hui as Chief Financial Officer, Company Secretary, Authorized Representative and Legal Process Agent.

XD INC (02400) spent HK$7.8128 million on April 16th to repurchase 120,000 shares.

ZYY (08223) has successfully issued a total of 86 million subscribed shares, raising approximately 42.5 million Hong Kong dollars.